VistaGen Therapeutics Company Presentation

7 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 PH94B (neuroactive nasal spray) * Social Anxiety Disorder †1,2 Generalized Anxiety Disorder 5 Adjustment Disorder 4 Postpartum Anxiety 5 Perioperative Anxiety 5 Panic Disorder 5 PTSD 5 PH10 (neuroactive nasal spray) * Major Depressive Disorder 3 Postpartum Depression 5 Treatment-resistant Depression 5 Suicidal Ideation 5 AV-101 * (oral) with oral probenecid Major Depressive Disorder †6 Neuropathic Pain †6 LID associated with Parkinson’s Therapy 6 Epilepsy 6 Suicidal Ideation 6 1. Successful Phase 2 program completed; preparing for pivotal Phase 3 clinical development 2. EverInsight Therapeutics has exclusive rights to develop and commercialize in certain markets in Asia 3. Successful Phase 2A program completed; preparing for Phase 2B program 4. Preparing for open-label Phase 2A program 5. Assessing for potential Phase 2A program 6. Assessing for Phase 1B to support potential Phase 2A * The commencement of a ll potential studies noted above with dashed arrow bars is subject to U.S. FDA regulatory approval and the availability of sufficient funding. † FDA Fast Track designation granted Our CNS Pipeline